bearish
Samsung Biologics' Accounting Violation's Impact on Samsung C&T and Rest of the Korean Pharmas
166 Views01 May 2018 22:55
On May 1st, 2018, Korea's Financial Supervisory Service (FSS) announced that Samsung Biologics Co., Ltd (207940 KS) violated accounting rules after...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- FSS Vs. Samsung BioLogics - Latest Situation Update10 May 2018
- Samsung BioLogics - Market Sentiment Assessment05 May 2018
- Samsung BioLogics and Biogen: Who Had Control?04 May 2018
- Samsung Biologics' Accounting Violation's Impact on Samsung C&T and Rest of the Korean Pharmas01 May 2018
- Biosimilar Battlefield: Samsung Bioepis Forecast13 Sep 2017
- Reconsider the Samsung Bioepis Valuation11 Mar 2017
x